EGFR and central nervous system cancer: The IDH-wildtype gliomas were a focus of the cIMPACT-NOW Updates 3 and 6.4,5 Update three had suggested the term “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” for IDH-wildtype gliomas with any one of these: TERT promoter mutation or EGFR gene amplification or chromosome seven gain with chromosome 10 loss (+7/–10).